Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Toray Industries Inc | 3,765 |
| 2 | Resonac Corp | 2,895 |
| 3 | Kaneka Corp | 1,630 |
| 4 | Sumitomo Bakelite Co Ltd | 1,585 |
| 5 | Nippon Kayaku Co Ltd | 1,250 |
| 6 | Nissan Chemical Corp | 1,036 |
| 7 | Mitsui Chemicals Inc | 900 |
| 8 | Toyobo Co Ltd | 878 |
| 9 | General Electric Co | 858 |
| 10 | SABIC Global Technologies BV | 846 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | C08G | Polymers from non-vinyl bonds (e.g. polyamides, polyesters) | 27,884 |
| 2 | C08L | Polymer compositions (blends) | 23,983 |
| 3 | A61K | Medicinal preparations | 21,739 |
| 4 | A61P | Therapeutic activity (drug indications) | 19,715 |
| 5 | C08K | Polymer compositions (additives) | 13,576 |
| 6 | C08J | Working-up of plastics | 12,012 |
| 7 | Y10T | Cross-reference (technical subjects) | 8,425 |
| 8 | C07D | Heterocyclic compounds | 8,197 |
| 9 | C09D | Coatings, paints, varnishes | 7,282 |
| 10 | B32B | Layered products | 7,241 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Dapsone and promin for the treatment of dementia | 1996 | THE UNIVERSITY OF BRITISH COLUMBIA | 29 |
| COMBINATION OF DAPSONE WITH ADAPALENE | 2011 | Allergan Inc | 18 |
| DAPSONE TO TREAT ROSASCEA | 2009 | Tolmar Therapeutics Inc | 13 |
| Emulsifying composition containing dapsone | 2007 | キューエルティー・ユーエスエイ・インコーポレーテッド | 12 |
| EMULSIVE COMPOSITION CONTAINING DAPSONE | 2005 | Tolmar Therapeutics Inc | 10 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Leprosy Research and Treatment | 45 |
| 2 | Autoimmune Bullous Skin Diseases | 28 |
| 3 | Pneumocystis jirovecii pneumonia detection and treatment | 10 |
| 4 | Methemoglobinemia and Tumor Lysis Syndrome | 8 |
| 5 | Autoimmune and Inflammatory Disorders | 7 |
| 6 | Blood disorders and treatments | 7 |
| 7 | Celiac Disease Research and Management | 7 |
| 8 | Acne and Rosacea Treatments and Effects | 6 |
| 9 | Drug-Induced Adverse Reactions | 6 |
| 10 | Malaria Research and Control | 6 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Michael D. Coleman | Aston University | 21 |
| 2 | Takashi Hashimoto | Kurume University | 21 |
| 3 | R. J. W. Rees | National Institute for Medical Research | 17 |
| 4 | Michael F. Waters | United States Public Health Service | 15 |
| 5 | Brian Greenwood | MRC Unit the Gambia | 13 |
| 6 | A Girdhar | National JALMA Institute for Leprosy & Other Mycobacterial Diseases | 12 |
| 7 | A. C. McDOUGALL | University of Oxford | 12 |
| 8 | G Ramu | National JALMA Institute for Leprosy & Other Mycobacterial Diseases | 12 |
| 9 | S Balakrishnan | 12 | |
| 10 | A. B. G. Laing | MRC Unit the Gambia | 11 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Relapsing polychondritis — REPORT OF TEN CASES | 1979 | 639 | Coagulation, Bradykinin, Polyphosphates, and Angioedema |
| Evaluation of Atypical Cytochrome P450 Kinetics with Two-Substrate Models: Evidence That Multiple Substrates Can Simultaneously Bind to Cytochrome P450 Active Sites | 1998 | 519 | Computational Drug Discovery Methods |
| PLASMODIUM VIVAX RESISTANCE TO CHLOROQUINE? | 1989 | 519 | Malaria Research and Control |
| Dapsone and sulfones in dermatology: Overview and update | 2001 | 446 | Drug-Induced Adverse Reactions |
| Clinical Manifestations of AIDS in the Era of Pneumocystis Prophylaxis | 1993 | 412 | Tuberculosis Research and Epidemiology |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the chemical composition and molecular structure of Dapsone?
What are the primary clinical research areas associated with Dapsone?
What are examples of recent patent applications for Dapsone formulations?
Which organizations have published significant research on Dapsone?
How has patent activity for compounds related to Dapsone evolved in recent years?